Black Diamond Therapeutics Inc [NASDAQ: BDTX] stock went on a downward path that fall over -22.03% on Wednesday, amounting to a one-week price decrease of less than -30.49%.
Over the last 12 months, BDTX stock rose by 25.70%. The one-year Black Diamond Therapeutics Inc stock forecast points to a potential upside of 71.47. The average equity rating for BDTX stock is currently 1.33, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $153.26 million, with 56.94 million shares outstanding and 44.75 million shares in the current float. Compared to the average trading volume of 1.03M shares, BDTX stock reached a trading volume of 10154114 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Black Diamond Therapeutics Inc [BDTX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BDTX shares is $9.43 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BDTX stock is a recommendation set at 1.33. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Guggenheim have made an estimate for Black Diamond Therapeutics Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on Dec-04-25. While these analysts kept the previous recommendation, Piper Sandler raised their target price to Overweight. The new note on the price target was released on November 18, 2025, representing the official price target for Black Diamond Therapeutics Inc stock. Previously, the target price had yet another raise to $8, while Stifel analysts kept a Buy rating on BDTX stock.
The Price to Book ratio for the last quarter was 1.21, with the Price to Cash per share for the same quarter was set at 2.38. Price to Free Cash Flow for BDTX in the course of the last twelve months was 7.18 with Quick ratio for the last quarter at 8.94.
BDTX Stock Performance Analysis:
Black Diamond Therapeutics Inc [BDTX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -30.49. With this latest performance, BDTX shares dropped by -31.90% in over the last four-week period, additionally plugging by 5.91% over the last 6 months – not to mention a rise of 25.70% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BDTX stock in for the last two-week period is set at 26.15, with the RSI for the last a single of trading hit 0.36, and the three-weeks RSI is set at 0.31 for Black Diamond Therapeutics Inc [BDTX]. The present Moving Average for the last 50 days of trading for this stock 3.88, while it was recorded at 3.50 for the last single week of trading, and 2.69 for the last 200 days.
Insight into Black Diamond Therapeutics Inc Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Black Diamond Therapeutics Inc [BDTX] shares currently have an operating margin of 16.94% and a Gross Margin at 99.51%. Black Diamond Therapeutics Inc’s Net Margin is presently recorded at 30.71%.
Black Diamond Therapeutics Inc (BDTX) Capital Structure & Debt Analysis
According to recent financial data for Black Diamond Therapeutics Inc. ( BDTX), the Return on Equity (ROE) stands at 19.23%, reflecting robust shareholder value creation. The Return on Assets (ROA) is 14.54%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Black Diamond Therapeutics Inc’s Return on Invested Capital (ROIC) is 15.12%, showcasing its effectiveness in deploying capital for earnings.
Black Diamond Therapeutics Inc (BDTX) Efficiency & Liquidity Metrics
Based on Black Diamond Therapeutics Inc’s (BDTX) latest financial statements, the Debt-to-Equity Ratio is 0.16%, indicating its reliance on debt financing relative to shareholder equity.
Black Diamond Therapeutics Inc (BDTX) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Black Diamond Therapeutics Inc. (BDTX) effectively leverages its workforce, generating an average of $895833.33 per employee. The company’s liquidity position is robust, with a Current Ratio of 8.94% and a Quick Ratio of 8.94%, indicating strong ability to cover short-term liabilities.
BDTX Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BDTX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Black Diamond Therapeutics Inc go to 12.97%.
Black Diamond Therapeutics Inc [BDTX] Institutonal Ownership Details
There are presently around $79.44%, or 79.96%% of BDTX stock, in the hands of institutional investors. The top three institutional holders of BDTX stocks are: T. ROWE PRICE INVESTMENT MANAGEMENT, INC. with ownership of 10.66 million shares, which is approximately 20.5751%. BELLEVUE GROUP AG, holding 8.52 million shares of the stock with an approximate value of $$39.69 million in BDTX stocks shares; and BELLEVUE GROUP AG, currently with $$20.73 million in BDTX stock with ownership which is approximately 8.5869%.
